financetom
Business
financetom
/
Business
/
Central Bank of India Q2 net profit zooms 90% to ₹605 crore on strong NII
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Central Bank of India Q2 net profit zooms 90% to ₹605 crore on strong NII
Oct 20, 2023 9:43 AM

State-owned Central Bank of India on Friday (October 20) reported a 90.3% year-on-year (YoY) jump in net profit at ₹605.4 crore for the second quarter that ended September 30, 2023.

In the corresponding quarter last year, the Central Bank of India posted a net profit of ₹318.2 crore, the company said in a regulatory filing.

Net interest income (NII), which is the difference between the interest income a bank earns from its lending activities and the interest it pays to depositors, rose 10.2%, coming at ₹3,027.7 crore against ₹2,747.5 crore in the corresponding quarter of FY23.

Also Read: Kajaria Ceramics Q2 Results | Net profit rises 55% to ₹108 crore, declares dividend of Rs 6 per share

The gross non-performing asset (GNPA) stood at 4.62% in the September quarter against 4.95% in the June quarter. Net NPA came at 1.640% against 1.75% quarter-on-quarter.

In monetary terms, gross NPA stood at ₹10,666.03 crore against ₹ 10,890.84 crore quarter-on-quarter, whereas net NPA came at ₹3,664.22 crore against ₹3,717.75 crore quarter-on-quarter.

Provision and contingencies declined to ₹967 crore as against ₹1,125 crore in the same period a year ago. Provision Coverage Ratio improved to 92.54 in the quarter from 89.20 in the corresponding period a year ago.

Also Read: Laurus Labs Q2 Results | Net profit slumps 84% to ₹37 crore, misses estimates

Net Interest Margin improved to 3.53% as against 3.12% last year, it said. The capital adequacy ratio of the bank increased to 14.82% as compared to 13.56%. The bank's total business grew by 11.51% to ₹6,02,284 crore vis--vis ₹ 5,40,130 in the second quarter of the previous fiscal.

The results came after the close of the market hours. Shares of Central Bank of India Ltd ended at ₹46.85, down by ₹0.15, or 0.32 percent on the BSE.

First Published:Oct 20, 2023 6:43 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
CrowdStrike's Channel Success Will Continue as Growth Catalyst, Truist Securities Says
CrowdStrike's Channel Success Will Continue as Growth Catalyst, Truist Securities Says
Aug 28, 2025
08:39 AM EDT, 08/28/2025 (MT Newswires) -- CrowdStrike's ( CRWD ) channel success will continue as a growth catalyst as its partners sourced more than 60% of new business in fiscal Q2, Truist Securities said in a Wednesday note. The cybersecurity technology firm posted solid fiscal Q2 results due to robust platform demand, Falcon Flex, and deals, analysts led by...
Oil Edges Down as the Market Looks to This Weekend's End to the Summer Driving Season
Oil Edges Down as the Market Looks to This Weekend's End to the Summer Driving Season
Aug 28, 2025
08:38 AM EDT, 08/28/2025 (MT Newswires) -- Oil prices edged down early on Thursday but remained firmly rangebound as traders anticipate the coming end of high-demand U.S. summer driving season while waiting to see if India will continue to defy 50% secondary sanctions on its imports into the United States for buying Russian oil. West Texas Intermediate crude oil for...
Burlington Stores Raises Annual Outlook As CEO Highlights Strong Margins
Burlington Stores Raises Annual Outlook As CEO Highlights Strong Margins
Aug 28, 2025
Burlington Stores, Inc. ( BURL ) stock surged after it posted second-quarter fiscal 2025 revenue of $2.705 billion, up 10% from a year earlier and above the $2.652 billion consensus estimate. Comparable store sales rose 5%. Net income was $94 million, or $1.47 per diluted share, versus $74 million, or $1.15 per share, a year ago. Adjusted earnings were $1.72...
US FDA approves Teva Pharmaceuticals' generic obesity drug
US FDA approves Teva Pharmaceuticals' generic obesity drug
Aug 28, 2025
Aug 28 (Reuters) - The U.S. Food and Drug Administration has approved Teva Pharmaceuticals' cheaper generic version of Novo Nordisk's older weight-loss drug, Saxenda, the Israel-based company said on Thursday. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved